GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (OTCPK:LBLTF) » Definitions » Debt-to-Asset

Lattice Biologics (Lattice Biologics) Debt-to-Asset : 0.00 (As of Jun. 2021)


View and export this data going back to 2001. Start your Free Trial

What is Lattice Biologics Debt-to-Asset?

Lattice Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $0.00 Mil. Lattice Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $0.00 Mil. Lattice Biologics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2021 was $0.61 Mil. Lattice Biologics's debt to asset for the quarter that ended in Jun. 2021 was 0.00.


Lattice Biologics Debt-to-Asset Historical Data

The historical data trend for Lattice Biologics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Debt-to-Asset Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.62 0.70 0.66 0.94 1.04

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 1.04 1.15 - -

Competitive Comparison of Lattice Biologics's Debt-to-Asset

For the Medical Devices subindustry, Lattice Biologics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lattice Biologics's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Lattice Biologics's Debt-to-Asset falls into.



Lattice Biologics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Lattice Biologics's Debt-to-Asset for the fiscal year that ended in Sep. 2020 is calculated as

Lattice Biologics's Debt-to-Asset for the quarter that ended in Jun. 2021 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lattice Biologics  (OTCPK:LBLTF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Lattice Biologics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Lattice Biologics (Lattice Biologics) Business Description

Traded in Other Exchanges
N/A
Address
512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (Lattice Biologics) Headlines

No Headlines